As OBP-702 treatment significantly increased the tumor infiltration of CD8+ T cells (Figure 5F), the anti-tumor effect of combination therapy with PD-1 blockade and OBP-702 was investigated further using the syngeneic mouse model of subcutaneous PAN02 tumors. Here, CD8A is linked to neoplasm.